ARS Pharmaceuticals (SPRY) Stock Forecast & Price Target

Compare

544 Followers

See the Price Targets and Ratings of:

All Analysts

Top Analysts

Premium

SPRY Analyst Ratings

Strong Buy

4 Buy

0 Hold

0 Sell

Based on 4 analysts giving stock ratings to

ARS

Pharmaceuticals

in the past 3 months

TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months

SPRY Stock 12 Month Forecast

Average Price Target

$32.50

▲(196.80% Upside)

Based on 4 Wall Street analysts offering 12 month price targets for ARS Pharmaceuticals in the last 3 months. The average price target is $32.50 with a high forecast of $35.00 and a low forecast of $30.00. The average price target represents a 196.80% change from the last price of $10.95.

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"7":"$7","36":"$36","14.25":"$14.25","21.5":"$21.5","28.75":"$28.8"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":35,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$35.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":32.5,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$32.50</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":30,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$30.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[7,14.25,21.5,28.75,36],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Mar<br/>2025","6":"Jul<br/>2025","9":"Oct<br/>2025","12":"Jan<br/>2026","25":"Jan<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,11.65,13.446153846153846,15.242307692307692,17.03846153846154,18.834615384615386,20.630769230769232,22.426923076923078,24.223076923076924,26.01923076923077,27.815384615384616,29.611538461538466,31.407692307692308,33.20384615384616,{"y":35,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,11.65,13.253846153846155,14.857692307692307,16.46153846153846,18.065384615384616,19.669230769230772,21.27307692307692,22.876923076923077,24.480769230769234,26.084615384615386,27.68846153846154,29.292307692307695,30.896153846153844,{"y":32.5,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,11.65,13.061538461538461,14.473076923076924,15.884615384615385,17.296153846153846,18.70769230769231,20.119230769230768,21.53076923076923,22.942307692307693,24.353846153846156,25.76538461538462,27.176923076923078,28.588461538461537,{"y":30,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":13.32,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 11, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":10.55,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 14, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":13.02,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 9, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":10.48,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":14.16,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 21,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":14.46,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 21,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":16.09,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":17.18,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":11.12,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":10.09,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":8.96,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":9.4,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":11.65,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Highest Price Target$35.00

Average Price Target$32.50

Lowest Price Target$30.00

The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts

Lachlan Hanbury Brown

William Blair

Buy

―

Reiterated

01/09/26

ARS Pharmaceuticals: Buy Rating Reaffirmed on Improved Competitive Outlook After Aquestive’s Anaphylm SetbackWe believe Aquestive’s announcement that the FDA has identified deficiencies that preclude labeling discussions for Anaphylm ahead of its January 31 PDUFA suggests a CRL is the likely outcome. While not entirely unexpected, we believe this news is a positive for shares in ARS, as it likely removes (or at least delays) the potential for a near-term competitor in the needle-free epinephrine space, which has been an overhang on the stock. While we await a final review decision and details on a potential path forward, this leaves neffy as the only needle-free epinephrine device on the market for the time being, giving ARS more time to establish neffy as the needle-free option before potential future competition.

Ryan Deschner

Raymond James

Buy

―

Reiterated

01/09/26

Regulatory Setbacks for Anaphylm Enhance ARS Pharmaceuticals’ Competitive Position and Support SPRY Buy RatingWe also note that the 150-day response deadline for SPRY’s Citizen’s Petition is in late February.

Kyle Bauser

Roth MKM

$30

Buy

173.97%

Upside

Reiterated

01/02/26

Is ARS Pharmaceuticals a buy?Todays news is ahead of expectations, as we had anticipated China approval in 1H26, Bauser said.

Andreas Argyrides

Oppenheimer

$40→$35

Buy

219.63%

Upside

Reiterated

11/10/25

ARS Pharmaceuticals (SPRY) Gets a Buy from Oppenheimer

Joshua Schimmer

Cantor Fitzgerald

$25

Buy

128.31%

Upside

Reiterated

09/06/25

Cantor Fitzgerald Sticks to Its Buy Rating for ARS Pharmaceuticals (SPRY)

Roanna Ruiz

Leerink Partners

$28

Buy

155.71%

Upside

Reiterated

08/14/25

Leerink Partners Sticks to Their Buy Rating for ARS Pharmaceuticals (SPRY)

Louise Chen

Scotiabank

$30

Buy

173.97%

Upside

Reiterated

05/15/25

Analysts' Top Healthcare Picks: ARS Pharmaceuticals (SPRY), Gain Therapeutics (GANX)

Analyst Type

Any

Human Analysts

Ranks

Any

Analyst Rating

Any

Upside/ Downside

Any

Action

Any

Lachlan Hanbury Brown

William Blair

Buy

―

Reiterated

01/09/26

Ryan Deschner

Raymond James

Buy

―

Reiterated

01/09/26

Kyle Bauser

Roth MKM

$30

Buy

173.97%

Upside

Reiterated

01/02/26

Is ARS Pharmaceuticals a buy?Todays news is ahead of expectations, as we had anticipated China approval in 1H26, Bauser said.

Andreas Argyrides

Oppenheimer

$40→$35

Buy

219.63%

Upside

Reiterated

11/10/25

ARS Pharmaceuticals (SPRY) Gets a Buy from Oppenheimer

Joshua Schimmer

Cantor Fitzgerald

$25

Buy

128.31%

Upside

Reiterated

09/06/25

Cantor Fitzgerald Sticks to Its Buy Rating for ARS Pharmaceuticals (SPRY)

Roanna Ruiz

Leerink Partners

$28

Buy

155.71%

Upside

Reiterated

08/14/25

Leerink Partners Sticks to Their Buy Rating for ARS Pharmaceuticals (SPRY)

Louise Chen

Scotiabank

$30

Buy

173.97%

Upside

Reiterated

05/15/25

Analysts' Top Healthcare Picks: ARS Pharmaceuticals (SPRY), Gain Therapeutics (GANX)

Stocks with the Highest Top Analyst Consensus in the Healthcare Sector

xxx

Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering ARS Pharmaceuticals

3 Months

xxx

Success Rate

6/8 ratings generated profit

Average Return

+9.03%

reiterated a xxx

rating 4 days ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 3 Months would result in 75.00% of your transactions generating a profit, with an average return of +9.03% per trade.

1 Year

Andreas ArgyridesOppenheimer

Success Rate

8/11 ratings generated profit

Average Return

+91.58%

reiterated a buy rating 2 months ago

Copying Andreas Argyrides's trades and holding each position for 1 Year would result in 72.73% of your transactions generating a profit, with an average return of +91.58% per trade.

2 Years

xxx

Success Rate

10/11 ratings generated profit

Average Return

+101.50%

reiterated a xxx

rating 2 months ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 2 Years would result in 90.91% of your transactions generating a profit, with an average return of +101.50% per trade.

The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

SPRY Analyst Recommendation Trends

Rating

Sep 25

Oct 25

Nov 25

Dec 25

Jan 26

Strong Buy

Buy

Hold

Sell

Strong Sell

total

In the current month, SPRY has received 7 Buy Ratings, 4 Hold Ratings, and 0 Sell Ratings. SPRY average Analyst price target in the past 3 months is 32.50.

Each month's total comprises the sum of three months' worth of ratings.

SPRY Financial Forecast

SPRY Earnings Forecast

Next quarter’s earnings estimate for SPRY is -$0.42 with a range of -$0.57 to -$0.24. The previous quarter’s EPS was -$0.52. SPRY beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 57.07% of the time in the same period. In the last calendar year SPRY has Performed in-line its overall industry.

SPRY Sales Forecast

Next quarter’s sales forecast for SPRY is $26.94M with a range of $21.80M to $32.90M. The previous quarter’s sales results were $32.50M. SPRY beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 47.62% of the time in the same period. In the last calendar year SPRY has Performed in-line its overall industry.

SPRY Stock Forecast FAQ

What is SPRY’s average 12-month price target, according to analysts?

Based on analyst ratings, Ars Pharmaceuticals, Inc.’s 12-month average price target is 32.50.

What is SPRY’s upside potential, based on the analysts’ average price target?

Ars Pharmaceuticals, Inc. has 196.80% upside potential, based on the analysts’ average price target.

Can I see which stocks the top-ranking analysts are rating?

Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.

How can I follow the stock ratings of top Wall Street analysts?

Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.

Is SPRY a Buy, Sell or Hold?

Ars Pharmaceuticals, Inc. has a consensus rating of Strong Buy which is based on 4 buy ratings, 0 hold ratings and 0 sell ratings.

What is Ars Pharmaceuticals, Inc.’s price target?

The average price target for Ars Pharmaceuticals, Inc. is 32.50. This is based on 4 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is $35.00 ,the lowest forecast is $30.00. The average price target represents 196.80% Increase from the current price of $10.95.

What do analysts say about Ars Pharmaceuticals, Inc.?

Ars Pharmaceuticals, Inc.’s analyst rating consensus is a Strong Buy. This is based on the ratings of 4 Wall Streets Analysts.

How can I buy shares of SPRY?

Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.

ARS Pharmaceuticals (SPRY) Stock Forecast & Price Target

SPRY Analyst Ratings

SPRY Stock 12 Month Forecast

Average Price Target

Detailed List of Analyst Forecasts​

Best Analysts Covering ARS Pharmaceuticals

SPRY Analyst Recommendation Trends

SPRY Financial Forecast

SPRY Earnings Forecast

SPRY Sales Forecast

SPRY Stock Forecast FAQ

Detailed List of Analyst Forecasts